Journal of Thyroid Cancer publishes rigorous thyroid cancer research that advances diagnosis, treatment, and survivorship care.

Follow these guidelines to ensure a smooth editorial review and production process.

• Use clear, concise language and define all abbreviations
• Include structured abstracts with objectives, methods, results, and conclusions
• Provide keywords that reflect thyroid cancer subtypes and methods
• Ensure references are complete and include DOIs where available

• STROBE for observational studies
• CONSORT for randomized trials
• PRISMA for systematic reviews
• CARE for case reports
• TREND for non randomized evaluations

• Include ethics approvals and informed consent statements
• Provide data availability statements and repository links
• Describe diagnostic criteria and staging methods
• Document patient privacy safeguards and deidentification

• Title page with author affiliations and corresponding author details
• Abstract and keywords
• Introduction describing clinical context and research gap
• Methods including diagnostic and treatment protocols
• Results with tables, figures, and statistical analysis
• Discussion highlighting implications for clinical care

Provide high resolution figures and editable tables. Ensure all units and abbreviations are defined. Figures should be cited in order and include descriptive captions.

• Cover letter explaining novelty and clinical relevance
• Conflict of interest and funding disclosures
• Ethics approvals and consent documentation
• Data availability statement
• Figure and table files uploaded
• Report thyroid cancer subtype (papillary, follicular, medullary, anaplastic) and histologic variant.
• Include AJCC staging and ATA risk stratification details.
• Describe ultrasound features using TI-RADS or equivalent scoring.
• Report cytology classification using the Bethesda system.
• Provide tumor size, multifocality, and extrathyroidal extension data.
• Describe lymph node assessment methods and dissection extent.
• Report surgical approach and margin status (R0/R1/R2).
• Include postoperative thyroglobulin levels and antibody status.
• Specify radioactive iodine dose, preparation method, and response criteria.
• Define recurrence, persistence, and follow up intervals clearly.
• Describe imaging modalities used for surveillance and response assessment.
• Report complication rates such as hypocalcemia or recurrent laryngeal nerve injury.
• Provide survival outcomes and event definitions (DFS, OS, PFS).
• Include molecular profiling methods and mutation panels used.
• Report BRAF, RAS, RET, TERT, and other driver alterations when tested.
• Clarify indications for targeted therapies and response metrics.
• Describe criteria for RAI refractory disease.
• Include endocrine outcomes such as TSH suppression targets and dosing.
• Report quality of life or patient reported outcomes when available.
• Document consent procedures and ethics approvals for clinical studies.
• Describe inclusion/exclusion criteria and referral pathways.
• Provide details on family history or MEN2 screening when relevant.
• Clarify pathology review standards and interobserver agreement.
• Include reporting of vascular invasion or capsular invasion.
• Provide data on tumor microenvironment markers or immune profiling.
• Report use of RECIST or other response criteria for systemic therapy.
• Include trial registration identifiers for prospective studies.
• Describe statistical power calculations or sample size justification.
• Report handling of missing data and sensitivity analyses.
• Provide data availability statements and repository access details.
• Clarify whether imaging or pathology data are shareable and how.
• Describe multidisciplinary team involvement in treatment planning.
• Report adherence to guideline recommendations or deviations.
• Provide stratified outcomes by risk group or stage.
• Document long term adverse events or endocrine complications.
• Include details on ablative versus adjuvant RAI strategies.
• Report use of PET/CT or advanced imaging and rationale.
• Describe histopathologic criteria for aggressive variants.
• Provide local or regional recurrence management details.
• Clarify timing between diagnosis, surgery, and adjuvant therapy.
• Report preoperative vocal cord assessment and laryngeal nerve monitoring details.
• Include postoperative calcium management protocols and outcomes.
• Describe tumor growth patterns and variant classification criteria.
• Report detailed lymph node mapping and nodal yield metrics.
• Include timing and criteria for completion thyroidectomy when applicable.
• Provide details on active surveillance protocols for low risk disease.
• Report use of minimally invasive or robotic surgical approaches.
• Clarify criteria for lobectomy versus total thyroidectomy.
• Include outcomes stratified by sex and age when relevant.
• Report use of molecular risk calculators or nomograms.
• Describe dose adjustments for thyroid hormone suppression therapy.
• Include monitoring schedules for thyroglobulin and imaging.
• Report adverse events related to systemic therapies.
• Provide cost effectiveness or resource utilization analyses when available.
• Describe multidisciplinary tumor board decision pathways.
• Report use of intraoperative nerve monitoring and outcomes.
• Describe postoperative monitoring for hypoparathyroidism.
• Include data on incidental findings and management decisions.
• Provide details on active surveillance eligibility criteria.
• Report time to recurrence and methods of detection.
• Describe patient selection for minimally invasive approaches.
• Provide a structured abstract with clear objectives, methods, results, and conclusions.
• Use consistent thyroid oncology terminology and define abbreviations at first use.
• Include a data availability statement with repository links or accession numbers.
• Report statistical tests, effect sizes, and confidence intervals where applicable.
• Describe patient cohorts, inclusion criteria, and staging methods.
• Provide detailed surgical or treatment protocols.
• Report imaging modalities, timing, and diagnostic thresholds.
• Include clear figure legends and indicate sample sizes and data sources.
• Confirm references include DOIs where available and match in text citations.
• Disclose funding sources, grant numbers, and potential conflicts of interest.
• Report ethics approvals, informed consent, and privacy safeguards.
• Clarify guidelines referenced and any deviations.
• Include a brief limitations statement that addresses generalizability.
• Provide repository links for code, models, or analysis scripts when shared.
• State whether preprints exist and disclose prior dissemination.
• Describe how raw data and code can be accessed, including access controls.
• Report quality control for pathology or imaging review.
• Include details on adverse event monitoring for therapies.
• Provide response criteria used for systemic therapies.
• Clarify primary and secondary endpoint definitions and timing.
• Report trial registration identifiers when applicable.
• Define units for all measurements and ensure consistent reporting.
• Include details on preoperative imaging protocols and reporting standards.
• Report cytology adequacy rates and nondiagnostic handling.
• Clarify definitions for biochemical versus structural recurrence.
• Provide risk stratification criteria used for adjuvant therapy decisions.
• Include details on tumor margins and capsular invasion reporting.
• Report protocol deviations and their impact on outcomes.
• Describe adjustments for competing risks in survival analyses.
• Provide subgroup analyses for aggressive variants when applicable.
• Report postoperative complication grading scales used.
• Include imaging response criteria for metastatic disease.
• Describe follow up frequency and lost to follow up handling.
• Provide clear definitions for treatment response categories.
• Describe surgical margin assessment methods in detail.
• Report lymph node yield and mapping protocols when relevant.
• Include details on radioiodine dosing preparation and withdrawal.
• Clarify definitions for biochemical persistence versus recurrence.
• Provide protocols for follow up imaging and laboratory monitoring.
• Report criteria for selecting adjuvant therapies.
• Describe handling of thyroid hormone suppression strategies.
• Include details on management of incidental thyroid carcinoma.

JTC is committed to rigorous, transparent publishing in thyroid cancer research and care. We emphasize reproducible clinical methods, clear reporting of diagnostic criteria, and ethical compliance across all article types.

The editorial office supports authors, editors, and reviewers with clear guidance and responsive communication. For questions about scope or workflow, contact [email protected].

We encourage continuous improvement in reporting practices and share updates that help the community maintain high standards in endocrine oncology, surgical outcomes, and translational thyroid research.